KRAZATI
Total Payments
$62.1M
Transactions
25,082
Doctors
6,685
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $22.8M | 7,249 | 3,768 |
| 2023 | $39.3M | 17,833 | 5,074 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $60.0M | 7,644 | 96.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.0M | 444 | 1.7% |
| Food and Beverage | $388,132 | 15,186 | 0.6% |
| Consulting Fee | $235,885 | 147 | 0.4% |
| Travel and Lodging | $187,650 | 444 | 0.3% |
| Honoraria | $125,428 | 61 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $51,695 | 20 | 0.1% |
| Education | $22,555 | 1,135 | 0.0% |
| Royalty or License | $5,905 | 1 | 0.0% |
Payments by Type
Research
$60.0M
7,644 transactions
General
$2.1M
17,438 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1 | Mirati Therapeutics, Inc. | $32.8M | 0 |
| A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy | Mirati Therapeutics, Inc. | $5.7M | 1 |
| A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation | Mirati Therapeutics, Inc. | $5.3M | 0 |
| A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination | Mirati Therapeutics, Inc. | $3.6M | 0 |
| STRATEGIC Alliance Agreement - RCTS#59451 | Mirati Therapeutics, Inc. | $3.2M | 0 |
| A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With MTAP Homozygous Deletion | Mirati Therapeutics, Inc. | $1.4M | 0 |
| A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on Adagrasib | Mirati Therapeutics, Inc. | $1.3M | 0 |
| A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib | Mirati Therapeutics, Inc. | $948,260 | 0 |
| A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | Mirati Therapeutics, Inc. | $910,278 | 0 |
| A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation | Mirati Therapeutics, Inc. | $816,537 | 0 |
| A Phase 1/2 Trial of MRTX849 in Combination With TNO155 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL 2 | Mirati Therapeutics, Inc. | $623,138 | 0 |
| A Phase 1/1b Trial of MRTX849 in Combination with Palbociclib in Patients with Advanced Solid Tumors with KRAS G12C Mutation | Mirati Therapeutics, Inc. | $614,997 | 0 |
| A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway | E.R. Squibb & Sons, L.L.C. | $482,942 | 0 |
| A Phase 1/2 Trial of MRTX849 in Combination with ABI-009 in Patients with Advanced Solid Tumors and Non-Small Cell Lung Cancer with KRAS G12C Mutation | Mirati Therapeutics, Inc. | $423,619 | 0 |
| A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutatio | Mirati Therapeutics, Inc. | $341,012 | 0 |
| Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | Mirati Therapeutics, Inc. | $330,315 | 0 |
| 849VS1 Verastem P1/2 Adagrasib + VS-6766 Combo | Mirati Therapeutics, Inc. | $240,820 | 0 |
| A Phase 1/1b Trial of MRTX849 in Combination With BI 1701963 in Patients With Advanced Solid Tumors With KRAS G12C Mutation | Mirati Therapeutics, Inc. | $147,065 | 0 |
| A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Adagrasib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 204) | Mirati Therapeutics, Inc. | $121,521 | 0 |
| Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study | Mirati Therapeutics, Inc. | $95,100 | 0 |
Top Doctors Receiving Payments for KRAZATI
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| William Oliver | — | Louisville, KY | $60.1M | 7,670 |
| , M.D., PH.D | Student in an Organized Health Care Education/Training Program | Rockledge, FL | $138,886 | 121 |
| , MD | Medical Oncology | Dallas, TX | $104,584 | 82 |
| , MD | Internal Medicine | Los Angeles, CA | $74,591 | 47 |
| , M.D | Hematology & Oncology | Baltimore, MD | $54,594 | 41 |
| , MD | Hematology & Oncology | New Orleans, LA | $42,984 | 27 |
| , M.D | Hematology & Oncology | Pleasant Hill, CA | $41,999 | 41 |
| , RN NP | Nurse Practitioner | Boston, MA | $39,038 | 87 |
| , M.D | Medical Oncology | Greensboro, NC | $38,838 | 32 |
| , MD | Hematology & Oncology | Orlando, FL | $38,378 | 35 |
| , CRNP | Nurse Practitioner | Baltimore, MD | $37,940 | 41 |
| , M.D | Hematology & Oncology | Germantown, TN | $34,267 | 34 |
| , MD | Medical Oncology | Minneapolis, MN | $33,323 | 39 |
| , M.D | Hematology & Oncology | Williamsport, PA | $30,707 | 26 |
| , M.D | Hematology & Oncology | Orlando, FL | $30,324 | 16 |
| , MD | Hematology & Oncology | Atlanta, GA | $29,910 | 16 |
| , MD | Hematology & Oncology | Wynnewood, PA | $29,906 | 40 |
| , MD | Medical Oncology | Mcallen, TX | $29,241 | 29 |
| , M.D | Medical Oncology | Huntington, WV | $28,632 | 32 |
| , MD | Hematology & Oncology | Chandler, AZ | $26,842 | 20 |
| , PA-C | Medical | Baltimore, MD | $24,191 | 72 |
| , M.D | Internal Medicine | Spartanburg, SC | $23,415 | 16 |
| , MD | Hematology & Oncology | Orange, CA | $22,409 | 17 |
| , M.D | Hematology & Oncology | La Jolla, CA | $22,032 | 16 |
| , MD | Hematology & Oncology | Kettering, OH | $21,887 | 12 |
Ad
Manufacturing Companies
- Mirati Therapeutics, Inc. $61.5M
- E.R. Squibb & Sons, L.L.C. $552,015
Product Information
- Type Drug
- Total Payments $62.1M
- Total Doctors 6,685
- Transactions 25,082
About KRAZATI
KRAZATI is a drug associated with $62.1M in payments to 6,685 healthcare providers, recorded across 25,082 transactions in the CMS Open Payments database. The primary manufacturer is Mirati Therapeutics, Inc..
Payment data is available from 2023 to 2024. In 2024, $22.8M was paid across 7,249 transactions to 3,768 doctors.
The most common payment nature for KRAZATI is "Unspecified" ($60.0M, 96.7% of total).
KRAZATI is associated with 20 research studies, including "A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1" ($32.8M).